Back to News
Market Impact: 0.4
Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Sanofi and Regeneron expanded their global collaboration to develop and commercialize four next-generation long-acting immunology antibodies targeting type 2 inflammation. The alliance broadens both companies' pipeline exposure in immunology and could support longer-term product growth, though no financial terms or development timelines were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
REGN0.65
SNY0.65
More News
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Jefferies raises Regeneron stock price target to $930 on partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- SoftBank completes final phase of $30 billion investment in OpenAI
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund